Sanofi’s rare disease drug Cablivi approved in the EU

The European Commission has approved Sanofi’s Cablivi, the first treatment for patients with the rare blood-clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP), which is also currently under priority review in the US.